Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01844180 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
A Phase 2 study, sponsored by Ono Pharma USA.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT01844180 is a Phase 2 study that has completed, run by Ono Pharma USA. The registered enrollment target is 200 participants.
The verdict
NCT01844180, a Phase 2 study, has completed, sponsored by Ono Pharma USA.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
Interventions
- DRUG ONO-2952
- DRUG ONO-2952 Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01844180
The ClinicalTrials.gov registry entry for NCT01844180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharma USA, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ONO-2952 is the first listed.
NCT01844180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01844180 about?
NCT01844180 is a clinical study titled "A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)". The objective of this study is to explore efficacy, safety and tolerability of ONO-2952 in female subjects with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).
What is the current status of trial NCT01844180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2013-04.
What interventions are being tested in trial NCT01844180?
The interventions under investigation include: ONO-2952 (DRUG), ONO-2952 Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT01844180?
This trial is sponsored by Ono Pharma USA, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.